β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

NCT03123484 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: β-elemene
DRUG: EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)

Sponsor

China Medical University, China

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]